Section Arrow
Quote
CMMB.NASDAQ
- Chemomab Therapeutics Ltd
Quotes are at least 15-min delayed:2026/05/22 22:16 EDT
Regular Hours
Last
 2.02
+0.2 (+10.99%)
Day High 
2.0859 
Prev. Close
1.82 
1-M High
1.95 
Volume 
90.79K 
Bid
2.02
Ask
2.09
Day Low
1.83 
Open
1.83 
1-M Low
1.45 
Market Cap 
13.10M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.71 
20-SMA 1.65 
50-SMA 1.68 
52-W High 5.768 
52-W Low 0.8288 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.12/-0.60
Enterprise Value
13.10M
Balance Sheet
Book Value Per Share
1.49
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
GOVXGeoVax Labs Inc.3.64+0.89+32.36%-- 
MTVAMetaVia Inc.3.85+0.98+34.15%-- 
AKTXAkari Therapeutics Plc18.27+13.13+255.45%-- 
LIMNLiminatus Pharma Inc0.1694-0.0766-31.14%-- 
IOVAIovance Biotherapeutics4.11+0.41+11.08%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.